Clinical Trials Directory

Trials / Completed

CompletedNCT02772523

Control and Intervention Programme on Alzheimer's Disease Risk Factors

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
409 (actual)
Sponsor
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Academic / Other
Sex
All
Age
45 Years – 78 Years
Healthy volunteers
Accepted

Summary

Recent epidemiologic studies are identifying a number of modifiable risk and protective factors that may influence in the incidence of Alzheimer's disease (AD). Therefore, the combination of an early detection of individuals at risk together with interventional studies targeted to the control of modifiable risk factors makes primary prevention programmes to become a new and real therapeutic strategy. In this scenario, the investigators have designed the ALFAlife study, a programme of control and intervention on the modifiable AD risk factors. Throughout this study, participants will be given a number of healthy lifestyle guidelines that are personalised depending on their specific risk profile. These guidelines refer to smoking and dietary habits and physical, cognitive and social activity. The investigators hypothesis is that the follow-up of these guidelines will favor a change of participants' lifestyle habits towards healthier ones. In addition, the investigators hypothesise that changes in these lifestyle habits will have an effect on objective physiological measures (such as blood pressure and cholesterol levels).

Conditions

Interventions

TypeNameDescription
OTHERLifestyle recommendationsDietary, and physical, cognitive and social activity recommendations

Timeline

Start date
2016-05-01
Primary completion
2018-01-01
Completion
2019-05-01
First posted
2016-05-13
Last updated
2020-07-21

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02772523. Inclusion in this directory is not an endorsement.